InMed Pharmaceuticals is a Vancouver-based clinical-stage pharmaceutical company developing proprietary small-molecule therapeutics that target CB1 and CB2 receptors. Its pipeline includes programs for Alzheimer’s disease, dry age-related macular degeneration and dermatological indications, and the company also references manufacturing and R&D capabilities through its broader platform.